Qiagen and Servier Collaborate on Development of Test for Acute Myeloid Leukemia Drug

Time Stamp: March 10, 2023 10:04 AM
Source Node: 2512733

Qiagen and Servier have recently announced a collaboration to develop a test for acute myeloid leukemia (AML) drug. The test will use Qiagen’s proprietary technology to detect the presence of a specific biomarker in blood samples that can be used to identify patients who may benefit from treatment with Servier’s drug, Rydapt.

The test will be based on Qiagen’s QuantiGene Plex technology, which is a multiplexed gene expression assay. This technology uses a single sample of blood to measure the expression of multiple genes associated with AML. By detecting the presence of these genes, the test will be able to identify patients who may benefit from treatment with Rydapt.

The collaboration between Qiagen and Servier is an important step forward in the development of personalized medicine for AML. By using a single blood sample to detect the presence of specific biomarkers, doctors will be able to better identify which patients are likely to respond to Rydapt and which are not. This will enable them to provide more tailored treatments for their patients, potentially leading to improved outcomes.

The collaboration between Qiagen and Servier is also a testament to the power of partnerships in the healthcare industry. By combining their respective expertise in diagnostics and drug development, the two companies have been able to create a test that could potentially revolutionize the way AML is treated.

Overall, the collaboration between Qiagen and Servier is an exciting development in the fight against AML. By creating a test that can detect the presence of specific biomarkers in blood samples, doctors will be able to better identify which patients are likely to respond to Rydapt and provide more tailored treatments for their patients. This could lead to improved outcomes for those suffering from AML, and is a testament to the power of partnerships in the healthcare industry.